Zevra Reports Fourth Quarter and Full Year 2025 Financial Results
Stocks in this Quantisnow insightHealth Care
Historical context for ZVRA
Across the 15 sessions after earlier ZVRA headlines, the stock closed higher 6 times and lower 9 times, with a median move of 2.0% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | ZVRA | SPY |
|---|---|---|---|
| Mar 5, 2026 | Zevra Therapeutics Appoints Justin Renz as Chief Financial Officer | -1.6% | -0.6% |
| Mar 2, 2026 | Zevra Therapeutics Announces Details for Q4 and Full Year 2025 Financial Results Call | +1.8% | +0.1% |
| Feb 25, 2026 | Zevra Therapeutics to Present at the Citizens Life Sciences Conference | -0.4% | +0.8% |
| Feb 24, 2026 | Transpire Bio Strengthens its Leadership Team with Appointment of LaDuane Clifton as Chief Financial Officer | +3.1% | +0.7% |
| Feb 4, 2026 | Zevra Therapeutics Presents Positive New Real-World Data on MIPLYFFA® in Patients with Neimann-Pick Disease Type C (NPC) at the 22nd Annual WORLDSymposium™ | -2.4% | -0.5% |
| Feb 2, 2026 | Zevra Therapeutics to Ring Nasdaq Stock Market Opening Bell on Monday, February 9, 2026 | +4.0% | +0.5% |
Quantisnow market dataNASDAQ
ZVRA
Zevra Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
Get push alerts for ZVRA
Full ZVRA profile on Quantisnow Follow ZVRA and get a push notification the moment its next story breaks.